---
layout: post
title: "复星医药：重组人源抗PD-L1与抗TIGIT双特异性抗体注射液临床试验获批"
date: 2022-03-17 16:57:16 +0800
categories: cailianshe
tags: 财联社新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/1.600196" data-code="600196|1|1" data-code2="600196|1|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.600196&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 600196_0" data-code="K 600196|1|1" data-code2="K 600196|1|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>复星医药公告，公司子公司复宏汉霖药品HLX301(重组人源抗PD-L1与抗TIGIT双特异性抗体注射液)获药品临床试验批准。<br /></p><p class="em_media">（文章来源：财联社）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202203172314033048>

[返回财联社新闻](//finews.withounder.com/category/cailianshe.html)｜[返回首页](//finews.withounder.com/)